세계의 POC(Point of Care) 진단 시장 예측(-2029년) : 제품별, 구입 방식별, 기술별, 샘플별, 최종사용자별

The point of care diagnostics market is estimated to reach USD 22.63 billion in 2029 from the forecasted value of USD 15.05 billion in 2024 at a CAGR of 8.5%. One of the primary reasons that will fuel POC testing is the favourable government initiatives and funding. Globally, governments consider these technologies essential in improving the accessibility of health care, bringing down costs, and enhancing outcomes for patients. Many governments also provide financial support in addition to the provision of grants with regulatory incentives to focus on the development and adoption of POC testing solutions. In developing countries with a lack of proper health care facilities, the governments encourage using POC devices abundantly, decentralizing tests for more underserved populations. Such supportive measures accelerate the adoption of POC diagnostics and thus are opening new market opportunities for diagnostic companies.

"Infectious disease testing products segment is expected to have the fastest growth rate in the point of care diagnostics market, by product, during the forecast period."

The point of care diagnostics market is segmented into glucose monitoring products, cardiometabolic monitoring products, infectious disease testing products, coagulation monitoring products, pregnancy & fertility testing products, tumor/cancer marker testing products, urinalysis testing products, cholesterol testing products, hematology testing products, drugs-of-abuse testing products, thyroid stimulating hormone testing products, fecal occult testing products, and other products, based on product. Infectious disease testing products are expected to witness the fastest growth in the point of care diagnostics market, mainly driven by the high prevalence of infectious diseases worldwide. The increased demand for fast, accurate, and decentralized healthcare diagnostic solutions for community clinics and rural health centers has been driving the demand in this segment. Improved technologies that include faster molecular diagnostics and enhanced immunoassay platforms enhance the speed and efficiency of accuracy in POC testing. Moreover, with an increase in public health initiatives and growing awareness of the POC solutions for infectious diseases, adoption of these products is increasing significantly.

"Blood samples segment accounted for the largest market share in the point of care diagnostics market, by sample, during the forecast period."

Based on sample, the point of care diagnostics market is bifurcated into blood samples, urine samples, nasal and oropharyngeal swabs, and other samples. The largest market share is held by blood samples in the point of care diagnostics market. Their critical role lies in detecting the broad spectrum of conditions such as diabetes, cardiovascular diseases, infectious diseases, and metabolic disorders. Blood-based tests are considered accurate, reliable, and offer have high turnaround times for results. Because of this reason, these are the most opted sample type for both clinical and near-patient environments. Also, efficiency in blood-based POC devices has been enhanced by the technological advancements which result in accurate results with minimum sample volumes. Additionally, chronic and infectious diseases continue to be on rise, which is accompanied by a high demand for rapid and convenient diagnostic solutions requiring blood-based tests, which has helped maintain the dominance of blood samples in this market.

"Asia Pacific: The fastest-growing market for point of care diagnostics"

The worldwide market for point of care diagnostics is categorized into North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC countries. The Asia Pacific region is experiencing significant growth in the point of care diagnostics market due to several factors. Government efforts to promote early disease detection, prevention, and regular health check-ups is a key driver, with a number of initiatives that encourage widespread health screening and timely intervention. These efforts, coupled with the rising healthcare expenditure across the region, have increased the accessibility and demand for diagnostic solutions. The increasing numbers of chronic conditions, such as diabetes in countries such as India and China have also increased the demand for fast and accurate diagnostic equipment. Improving public health results by early diagnosis and management is enabling more healthcare systems to become involved in adopting POC diagnostics in this region.

The break-up of the profile of primary participants in the point of care diagnostics market:

• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Other- 4%

The key players in this market are Abbott (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Danaher (US), QuidelOrtho Corporation (US), BD (US), Thermo Fisher Scientific Inc. (US), bioMerieux (France), BIOSYNEX SA (France), EKF Diagnostics Holdings plc (UK), Trinity Biotech (Ireland), Werfen (US), Nova Biomedical (US), SEKISUI Diagnostics (US), Boditech Med Inc. (South Korea), Grifols, S.A. (Spain), LifeScan IP Holdings, LLC (US), PTS Diagnostics (US), Eurolyser Diagnostica GmbH (Austria), Response Biomedical (Canada), Alfa Scientific Designs, Inc. (US), BTNX Inc. (Canada), Ascensia Diabetes Care Holdings AG (Switzerland), Fluxergy (US), Precision Biosensor, Inc. (South Korea), ACON Laboratories, Inc. (US), Menarini Diagnostics s.r.l (Italy), OraSure Technologies, Inc. (US), and Mankind Pharma (India) .

Research Coverage:

This research report categorizes the point of care diagnostics market by product (glucose monitoring products, cardiometabolic monitoring products, infectious disease testing products, coagulation monitoring products, pregnancy & fertility testing products, tumor/cancer marker testing products, urinalysis testing products, cholesterol testing products, hematology testing products, drugs-of-abuse testing products, thyroid stimulating hormone testing products, fecal occult testing products, and other products), by mode of purchase (OTC testing products and prescription-based testing products), by technology (immunoassays, molecular diagnostics, and biochemistry), by sample (blood samples, urine samples, nasal & oropharyngeal swabs, and other samples), by end user (clinical laboratories, ambulatory care facilities and physician offices, hospitals, critical care centers, and urgent care centers; home care settings and self-testing, and other end users) and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the point of care diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the point of care diagnostics market. Competitive analysis of upcoming startups in the point of care diagnostics market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall point of care diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (Growing incidence of infectious disease, increasing prevalence of chronic diseases, favourable government initiatives for point of care testing, and rising number of waived tests), opportunities (Increasing growth potential in emerging markets, rising inclination toward decentralized healthcare system, booming healthcare spending worldwide), restraints (Pricing pressure on manufacturers and stringent regulatory approval process for product commercialization), and challenges (Inadequate standardization with centralized lab methods and premium pricing of novel platforms) influencing the growth of the point of care diagnostics market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the point of care diagnostics market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the point of care diagnostics market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the point of care diagnostics market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Abbott (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), QuidelOrtho Corporation (US), and Danaher (US).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION AND REGIONS COVERED
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH APPROACH
  • 2.2.1 SECONDARY DATA
    • 2.2.1.1 Key secondary sources
    • 2.2.1.2 Key data from secondary sources
    • 2.2.1.3 Objectives
  • 2.2.2 PRIMARY DATA
    • 2.2.2.1 Key primary sources
    • 2.2.2.2 Key data from primary sources
    • 2.2.2.3 Key industry insights
    • 2.2.2.4 Breakdown of primary interviews
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 BOTTOM-UP APPROACH
    • 2.3.1.1 Company revenue estimation approach
    • 2.3.1.2 Presentations of companies and primary interviews
    • 2.3.1.3 Growth forecast
    • 2.3.1.4 CAGR projections
  • 2.3.2 TOP-DOWN APPROACH
• 2.4 DATA TRIANGULATION
• 2.5 MARKET SHARE ANALYSIS
• 2.6 RESEARCH ASSUMPTIONS
  • 2.6.1 PARAMETRIC ASSUMPTIONS
  • 2.6.2 GROWTH RATE ASSUMPTIONS
• 2.7 RESEARCH LIMITATIONS
• 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 POINT OF CARE DIAGNOSTICS MARKET OVERVIEW
• 4.2 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2024 VS. 2029
• 4.3 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024 VS. 2029
• 4.4 POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029
• 4.5 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2024 VS. 2029
• 4.6 POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029
• 4.7 POINT OF CARE DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing incidence of infectious diseases
    • 5.2.1.2 Increasing prevalence of chronic diseases
    • 5.2.1.3 Favorable government initiatives for point of care testing
    • 5.2.1.4 Rising number of waived tests
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Pricing pressure on manufacturers
    • 5.2.2.2 Stringent regulatory approval process for product commercialization
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increasing growth potential in emerging markets
    • 5.2.3.2 Rising inclination toward decentralized healthcare system
    • 5.2.3.3 Booming healthcare spending worldwide
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Inadequate standardization with centralized lab methods
    • 5.2.4.2 Premium pricing of novel platforms
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE, BY PRODUCT
  • 5.4.2 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY KEY PLAYER
  • 5.4.3 AVERAGE SELLING PRICE, BY REGION
    • 5.4.3.1 Average selling price of glucose monitoring test strips, by region
    • 5.4.3.2 Average selling price of infectious disease testing products, by region
    • 5.4.3.3 Average selling price of cardiometabolic monitoring products, by region
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 INVESTMENT AND FUNDING SCENARIO
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Immunoassays
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Molecular diagnostics
  • 5.9.3 ADJACENT TECHNOLOGIES
    • 5.9.3.1 Biochemical technologies
• 5.10 PATENT ANALYSIS
• 5.11 TRADE ANALYSIS
  • 5.11.1 IMPORT DATA FOR HS CODE 3822
  • 5.11.2 EXPORT DATA FOR HS CODE 3822
• 5.12 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.13 PORTER'S FIVE FORCES ANALYSIS
  • 5.13.1 BARGAINING POWER OF SUPPLIERS
  • 5.13.2 BARGAINING POWER OF BUYERS
  • 5.13.3 THREAT OF NEW ENTRANTS
  • 5.13.4 THREAT OF SUBSTITUTES
  • 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 KEY BUYING CRITERIA
• 5.15 IMPACT OF AI ON POINT OF CARE DIAGNOSTICS MARKET
  • 5.15.1 INTRODUCTION
  • 5.15.2 MARKET POTENTIAL OF AI IN POINT OF CARE DIAGNOSTICS MARKET
  • 5.15.3 AI USE CASES
  • 5.15.4 KEY COMPANIES IMPLEMENTING AI
  • 5.15.5 FUTURE OF AI IN POINT OF CARE DIAGNOSTICS MARKET
• 5.16 REGULATORY LANDSCAPE
  • 5.16.1 REGULATORY ANALYSIS
    • 5.16.1.1 North America
      • 5.16.1.1.1 US
      • 5.16.1.1.2 Canada
    • 5.16.1.2 Europe
      • 5.16.1.2.1 Germany
      • 5.16.1.2.2 UK
      • 5.16.1.2.3 France
      • 5.16.1.2.4 Italy
      • 5.16.1.2.5 Spain
    • 5.16.1.3 Asia Pacific
      • 5.16.1.3.1 China
      • 5.16.1.3.2 Japan
      • 5.16.1.3.3 India
      • 5.16.1.3.4 Australia
      • 5.16.1.3.5 South Korea
    • 5.16.1.4 Latin America
      • 5.16.1.4.1 Brazil
      • 5.16.1.4.2 Mexico
    • 5.16.1.5 Middle East
      • 5.16.1.5.1 Africa
  • 5.16.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.17 CASE STUDY ANALYSIS
  • 5.17.1 CASE STUDY 1: IMPACT OF POINT OF CARE PCR TESTING FOR COMMUNITY-ACQUIRED PNEUMONIA IN DENMARK
  • 5.17.2 CASE STUDY 2: ASSESSING POINT OF CARE VIRAL LOAD TESTING IMPACT ON HIV MONITORING IN NIGERIA
  • 5.17.3 CASE STUDY 3: CLINICAL IMPACT OF ROUTINE MOLECULAR POINT OF CARE TEST FOR INFLUENZA IN HOSPITALIZED ADULTS

6 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 GLUCOSE MONITORING PRODUCTS
  • 6.2.1 GLUCOSE MONITORING STRIPS
    • 6.2.1.1 Growing trend toward preventive healthcare to drive market
  • 6.2.2 GLUCOSE MONITORING METERS
    • 6.2.2.1 Growing technological advancements in glucose meters to propel market
  • 6.2.3 GLUCOSE MONITORING LANCETS & LANCING DEVICES
    • 6.2.3.1 Increasing tendency for home-based care and self-monitoring to aid growth
• 6.3 CARDIOMETABOLIC MONITORING PRODUCTS
  • 6.3.1 CARDIAC MARKER TESTING PRODUCTS
    • 6.3.1.1 Growing government support for cardiovascular diseases to drive market
  • 6.3.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS
    • 6.3.2.1 Need to optimize hospital workflow to favor growth
  • 6.3.3 HBA1C TESTING PRODUCTS
    • 6.3.3.1 Increasing recommendations by government healthcare authorities to boost market
• 6.4 INFECTIOUS DISEASE TESTING PRODUCTS
  • 6.4.1 RESPIRATORY INFECTION TESTING PRODUCTS
    • 6.4.1.1 Influenza testing products
      • 6.4.1.1.1 Need for targeted treatments to expedite growth
    • 6.4.1.2 Tuberculosis
      • 6.4.1.2.1 Increasing demand for diagnostic products and services to contribute to growth
    • 6.4.1.3 Other respiratory infection testing products
  • 6.4.2 HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS
    • 6.4.2.1 Growing rate of surgical-site infections to boost market
  • 6.4.3 TROPICAL DISEASE TESTING PRODUCTS
    • 6.4.3.1 Rising incidence of malaria and dengue to support growth
  • 6.4.4 SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS
    • 6.4.4.1 HIV testing products
      • 6.4.4.1.1 Growing availability and awareness of testing products to boost market
    • 6.4.4.2 Hepatitis testing products
      • 6.4.4.2.1 Hepatitis B testing products
        • 6.4.4.2.1.1 Increasing prevalence of liver infections to favor growth
      • 6.4.4.2.2 Hepatitis C testing products
        • 6.4.4.2.2.1 Need to combat hepatitis among high-risk subgroup populations to aid growth
    • 6.4.4.3 Syphilis testing products
      • 6.4.4.3.1 Need for early and accessible diagnosis to expedite growth
    • 6.4.4.4 Human papillomavirus testing products
      • 6.4.4.4.1 Rising cases of cervical cancer to promote growth
    • 6.4.4.5 Chlamydia trachomatis testing products
      • 6.4.4.5.1 Growing adoption of advanced techniques to drive market
    • 6.4.4.6 Neisseria gonorrhea testing products
      • 6.4.4.6.1 Rising incidence of gonorrhea and antimicrobial resistance to augment growth
    • 6.4.4.7 Herpes simplex virus testing products
      • 6.4.4.7.1 Increasing incidence of herpes to support growth
  • 6.4.5 CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS
    • 6.4.5.1 Rising cases among hospitalized patients to boost demand
  • 6.4.6 OTHER INFECTIOUS DISEASE TESTING PRODUCTS
• 6.5 COAGULATION MONITORING PRODUCTS
  • 6.5.1 PT/INR TESTING PRODUCTS
    • 6.5.1.1 Increasing number of atrial fibrillation cases to accelerate growth
  • 6.5.2 ACT/APTT TESTING PRODUCTS
    • 6.5.2.1 Rise in surgical procedures to speed up growth
• 6.6 PREGNANCY & FERTILITY TESTING PRODUCTS
  • 6.6.1 PREGNANCY TESTING PRODUCTS
    • 6.6.1.1 Increasing awareness about family planning to stimulate growth
  • 6.6.2 FERTILITY TESTING PRODUCTS
    • 6.6.2.1 Growing infertility issues to fuel market
• 6.7 TUMOR/CANCER MARKER TESTING PRODUCTS
  • 6.7.1 GROWING INVESTMENTS IN CANCER RESEARCH TO DRIVE MARKET
• 6.8 URINALYSIS TESTING PRODUCTS
  • 6.8.1 INCREASING PREVALENCE OF URINARY TRACT INFECTIONS TO AUGMENT GROWTH
• 6.9 CHOLESTEROL TESTING PRODUCTS
  • 6.9.1 RISING OBESITY AND CARDIOVASCULAR DISEASES TO FOSTER GROWTH
• 6.10 HEMATOLOGY TESTING PRODUCTS
  • 6.10.1 INCREASING CASES OF ANEMIA TO SUSTAIN GROWTH
• 6.11 DRUGS-OF-ABUSE TESTING PRODUCTS
  • 6.11.1 GROWING CONSUMPTION OF ILLICIT DRUGS TO FAVOR MARKET
• 6.12 THYROID-STIMULATING HORMONE TESTING PRODUCTS
  • 6.12.1 RISING PREVALENCE OF THYROID TO ENCOURAGE GROWTH
• 6.13 FECAL OCCULT TESTING PRODUCTS
  • 6.13.1 GROWING INCIDENCE OF CANCER TO PROPEL MARKET
• 6.14 OTHER PRODUCTS

7 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE

• 7.1 INTRODUCTION
• 7.2 PRESCRIPTION-BASED TESTING PRODUCTS
  • 7.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO AUGMENT GROWTH
• 7.3 OTC TESTING PRODUCTS
  • 7.3.1 GROWING PATIENT PREFERENCE FOR REMOTE HEALTHCARE TO PROPEL MARKET

8 POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY

• 8.1 INTRODUCTION
• 8.2 BIOCHEMISTRY
  • 8.2.1 INCREASING PREVALENCE OF URINARY TRACT INFECTIONS TO EXPEDITE GROWTH
• 8.3 IMMUNOASSAYS
  • 8.3.1 GROWING INCLINATION TOWARD DECENTRALIZED HEALTHCARE TO DRIVE MARKET
• 8.4 MOLECULAR DIAGNOSTICS
  • 8.4.1 RT-PCR
    • 8.4.1.1 Growing use of RT-PCR in proteomics and genomics to boost market
  • 8.4.2 INAAT
    • 8.4.2.1 Emerging new pathogens to facilitate growth

9 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE

• 9.1 INTRODUCTION
• 9.2 BLOOD SAMPLES
  • 9.2.1 GROWING APPLICATION OF BLOOD SAMPLES IN DISEASE DETECTION TO DRIVE MARKET
• 9.3 NASAL & OROPHARYNGEAL SWABS
  • 9.3.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO AID GROWTH
• 9.4 URINE SAMPLES
  • 9.4.1 NEED FOR EARLY DETECTION AND MONITORING OF DIABETES-RELATED COMPLICATIONS TO PROPEL MARKET
• 9.5 OTHER SAMPLES

10 POINT OF CARE DIAGNOSTICS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOME CARE SETTINGS AND SELF-TESTING
  • 10.2.1 INCREASING PREFERENCE AMONG WOMEN FOR CONFIDENTIALITY AND ACCESSIBILITY TO SUPPORT GROWTH
• 10.3 CLINICAL LABORATORIES
  • 10.3.1 GROWING IMPROVEMENTS IN AUTOMATED TESTING SERVICES TO BOOST MARKET
• 10.4 HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS
  • 10.4.1 RISING DEMAND FOR FAST DIAGNOSTIC SOLUTIONS TO SPUR GROWTH
• 10.5 AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES
  • 10.5.1 NEED FOR RAPID RESULT GENERATION AND IMMEDIATE PATIENT CARE TO AID GROWTH
• 10.6 OTHER END USERS

11 POINT OF CARE DIAGNOSTICS MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 Presence of advanced healthcare infrastructure and high healthcare expenditures to aid growth
  • 11.2.3 CANADA
    • 11.2.3.1 Rising incidence of diabetes and infectious diseases to support growth
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Increasing need for rapid and accurate diagnostic solutions to promote growth
  • 11.3.3 FRANCE
    • 11.3.3.1 Growing demand for accessible and convenient diagnostic tools to propel market
  • 11.3.4 UK
    • 11.3.4.1 Rising number of accredited clinical and hospital laboratories to sustain growth
  • 11.3.5 ITALY
    • 11.3.5.1 Growing burden of infectious and parasitic diseases to boost market
  • 11.3.6 SPAIN
    • 11.3.6.1 Rising prevalence of circulatory system diseases to contribute to growth
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 CHINA
    • 11.4.2.1 Increasing impact of diabetes on public health to amplify growth
  • 11.4.3 JAPAN
    • 11.4.3.1 Booming geriatric population to stimulate growth
  • 11.4.4 INDIA
    • 11.4.4.1 Increasing cases of chronic heart and kidney diseases to foster growth
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Growing research investments for next-gen point of care devices to boost market
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Growing focus on innovative diagnostic products to drive market
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Increasing public initiatives in healthcare to encourage growth
  • 11.5.3 MEXICO
    • 11.5.3.1 Need for frequent testing for disease management to expedite growth
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 GROWING OUTBREAKS OF INFECTIOUS DISEASES AND EMPHASIS ON PREVENTIVE HEALTHCARE TO DRIVE MARKET
  • 11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
• 11.7 GCC COUNTRIES
  • 11.7.1 BOOMING HEALTHCARE INFRASTRUCTURE TO FACILITATE GROWTH
  • 11.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN POINT OF CARE DIAGNOSTICS MARKET
• 12.3 REVENUE ANALYSIS, 2021-2023
• 12.4 MARKET SHARE ANALYSIS, 2023
• 12.5 COMPANY VALUATION AND FINANCIAL METRICS
• 12.6 BRAND/PRODUCT COMPARISON
  • 12.6.1 ABBOTT
  • 12.6.2 F. HOFFMANN-LA ROCHE LTD.
  • 12.6.3 NOVA BIOMEDICAL
• 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 12.7.1 STARS
  • 12.7.2 EMERGING LEADERS
  • 12.7.3 PERVASIVE PLAYERS
  • 12.7.4 PARTICIPANTS
  • 12.7.5 COMPANY FOOTPRINT, KEY PLAYERS, 2023
    • 12.7.5.1 Company footprint
    • 12.7.5.2 Region footprint
    • 12.7.5.3 Mode of purchase footprint
    • 12.7.5.4 Technology footprint
    • 12.7.5.5 Sample footprint
• 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 12.8.1 PROGRESSIVE COMPANIES
  • 12.8.2 RESPONSIVE COMPANIES
  • 12.8.3 DYNAMIC COMPANIES
  • 12.8.4 STARTING BLOCKS
• 12.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 12.9.1 DETAILED LIST OF KEY STARTUPS/SMES
  • 12.9.2 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
• 12.10 COMPETITIVE SCENARIO
  • 12.10.1 PRODUCT LAUNCHES AND APPROVALS
  • 12.10.2 DEALS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 ABBOTT
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product launches and approvals
      • 13.1.1.3.2 Deals
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Right to win
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses and competitive threats
  • 13.1.2 SIEMENS HEALTHINEERS AG
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product launches and approvals
      • 13.1.2.3.2 Deals
      • 13.1.2.3.3 Expansions
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Right to win
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses and competitive threats
  • 13.1.3 F. HOFFMANN-LA ROCHE LTD
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product launches and approvals
      • 13.1.3.3.2 Deals
      • 13.1.3.3.3 Expansions
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses and competitive threats
  • 13.1.4 DANAHER
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Deals
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Key strengths
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses and competitive threats
  • 13.1.5 QUIDELORTHO CORPORATION
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Product launches and approvals
      • 13.1.5.3.2 Deals
      • 13.1.5.3.3 Expansions
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Right to win
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses and competitive threats
  • 13.1.6 BD
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Deals
      • 13.1.6.3.2 Expansions
  • 13.1.7 THERMO FISHER SCIENTIFIC INC.
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Product launches and approvals
      • 13.1.7.3.2 Deals
  • 13.1.8 BIOMERIEUX
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product launches and approvals
      • 13.1.8.3.2 Deals
  • 13.1.9 BIOSYNEX SA
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Deals
  • 13.1.10 EKF DIAGNOSTICS HOLDINGS PLC
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Product launches and approvals
      • 13.1.10.3.2 Deals
      • 13.1.10.3.3 Expansions
  • 13.1.11 TRINITY BIOTECH
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Product launches and approvals
      • 13.1.11.3.2 Deals
  • 13.1.12 WERFEN
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Product launches and approvals
      • 13.1.12.3.2 Deals
  • 13.1.13 NOVA BIOMEDICAL
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Product launches and approvals
      • 13.1.13.3.2 Expansions
  • 13.1.14 SEKISUI DIAGNOSTICS
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
  • 13.1.15 BODITECH MED INC.
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Product launches and approvals
      • 13.1.15.3.2 Deals
      • 13.1.15.3.3 Expansions
• 13.2 OTHER PLAYERS
  • 13.2.1 GRIFOLS, S.A.
  • 13.2.2 LIFESCAN IP HOLDINGS, LLC
  • 13.2.3 PTS DIAGNOSTICS
  • 13.2.4 EUROLYSER DIAGNOSTICA GMBH
  • 13.2.5 RESPONSE BIOMEDICAL
  • 13.2.6 ALFA SCIENTIFIC DESIGNS, INC.
  • 13.2.7 BTNX INC.
  • 13.2.8 ASCENSIA DIABETES CARE HOLDINGS AG
  • 13.2.9 FLUXERGY
  • 13.2.10 PRECISION BIOSENSOR, INC.
  • 13.2.11 ACON LABORATORIES, INC.
  • 13.2.12 MENARINI DIAGNOSTICS S.R.L
  • 13.2.13 ORASURE TECHNOLOGIES, INC.
  • 13.2.14 MANKIND PHARMA

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS